Evidence map›Paper›PMID 31399952›Full record

ReviewImmunologic research2019

On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells.

Georgios Ntolkeras, Chrysanthi Barba, Athanasios Mavropoulos, Georgios K Vasileiadis, Efthymios Dardiotis, Lazaros I Sakkas, Georgios Hadjigeorgiou, Dimitrios P Bogdanos

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Georgios NtolkerasDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Biopolis, 40500, Larissa, Greece.
Chrysanthi BarbaDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Biopolis, 40500, Larissa, Greece.
Athanasios MavropoulosDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Biopolis, 40500, Larissa, Greece.
Georgios K VasileiadisDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Biopolis, 40500, Larissa, Greece.
Efthymios DardiotisDepartment of Neurology and Laboratory of Neurogenetics, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Viopolis, 40500, Larissa, Greece.
Lazaros I SakkasDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Biopolis, 40500, Larissa, Greece.
Georgios HadjigeorgiouDepartment of Neurology and Laboratory of Neurogenetics, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Viopolis, 40500, Larissa, Greece.
Dimitrios P BogdanosDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University General Hospital of Larissa, University of Thessaly, Biopolis, 40500, Larissa, Greece. bogdanos@med.uth.gr.ORCID http://orcid.org/0000-0002-9697-7902
University of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins, the cholesterol-lowering drugs, also possess immunomodulatory properties, affecting among others T cell activation and differentiation, antigen presentation, and regulatory T cell (Tregs) maintenance and differentiation. Their effects on autoagression have led investigators to assess their clinical significance in autoimmune disease, such as multiple sclerosis (MS), a chronic progressive demyelinating disease of autoimmune nature. The dysregulated immunity noted in MS features a profound shift from Tregs dominance to Th17 cell superiority. In this review, we discuss the immunobiological basis of statins, their role in autoimmunity related to MS, and the data from experimental models and human studies on their effect on Th17 cells.

Indexed as

Multiple SclerosisAnimalsDisease Models, AnimalHumansHydroxymethylglutaryl-CoA Reductase InhibitorsImmunologic FactorsTh17 CellsHydroxymethylglutaryl-CoA Reductase InhibitorsImmunologic FactorsAutoimmunityDemyelinationInflammationRegulationStatin

Identifiers

PMID31399952
OpenAlexW2967851856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.